Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant vs neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer
2010-021477-36Phase 3Completed
- Sponsor
- GSO
- Start
- Nov 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by GSO. Primary endpoint: Progression-free survival. Started Nov 2013; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-021477-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021477-36.